More generic versions of Zantac are being pulled from pharmacy shelves after officials discovered low levels of a probable carcinogen in the heartburn drug.
Concerns over a potential cancer risk stem from the presence of a likely carcinogen called NDMA, which has also prompted the recall of several versions of blood pressure-lowering pills. Separately, Appco issued a voluntary recall for all of its 150-milligram and 300-milligram Ranitidine Hydrochloride Capsules. The company said it's not aware of any adverse events tied to the prescription drug but advised patients to stop taking it and seek advice from their physicians on potential alternative treatments.
Emery Pharma, an Alameda, California-based private lab, conducted an analysis on the stability of ranitidine and found the drug appears to form NDMA when exposed to heat. In a petition filed Jan. 2 with the FDA, Emery also requested the agency suspend sales of all ranitidine products.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: L.A. Times Health - 🏆 364. / 59 Read more »
Source: DailyHealthTips - 🏆 710. / 51 Read more »